Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Relapsing Clostridium Difficile Infection
NCT01703494Phase 2Unknown
- Start
- Oct 2012
- Primary completion
- May 2015
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fecal microbiota in Clostridioides difficile infection (CDI) (2 arms). Primary endpoint: Clinical Cure at 8 weeks. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT01703494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01703494.